Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.
about
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.
P2860
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@ast
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@en
type
label
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@ast
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@en
prefLabel
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@ast
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@en
P2093
P2860
P1433
P1476
Multimodality vaccination agai ...... h a heterologous tier 2 virus.
@en
P2093
Barbara C Bachler
Diego A Vargas-Inchaustegui
Donald N Forthal
Egidio Brocca Cofano
Erwann P Loret
Francois Villinger
Girish Hemashettar
James G Else
Marjorie Robert-Guroff
Mingkui Zhou
P2860
P304
P356
10.1016/J.VACCINE.2014.08.065
P407
P577
2014-09-20T00:00:00Z